The results of the first head-to-head trial of Lilly's dual GLP-1/GIP ... sales will top $25 billion by 2030, ahead of Wegovy with $19.4 billion, while the versions of the drug to treat diabetes ...

Patients treated with semaglutide 7.2 mg achieved a 20.7% weight loss after 72 weeks compared with a reduction of 17.5% with ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy ... in the STEP 9 trial.

You've probably heard about the dramatic weight loss that can happen when you take Ozempic or Wegovy ... that's around 24 pounds vs. 4 pounds, respectively.) Another trial, published in the ...

Today was supposed to mark the beginning of the end for cheaper, knockoff versions of hot weight-loss drugs. The Food and Drug Administration wants bulk production of the copycats to stop ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide ... in a 2023–24 randomized clinical trial backed by Lilly.

The Danish company aims to position CagriSema as a more potent successor to its popular obesity drug Wegovy ... or about $8.4 billion, in 2024. But earlier trial results in people without diabetes ...

Diabetes and weight loss treatments such as Ozempic and Wegovy, known as GLP-1 agonists ... “The gold standard would be one large, randomised trial to answer this question, but this definitely ...